Results 21 to 30 of about 46,055 (312)

Production of glycoprotein vaccines in Escherichia coli

Microbial Cell Factories, 2010
Background Conjugate vaccines in which polysaccharide antigens are covalently linked to carrier proteins belong to the most effective and safest vaccines against bacterial pathogens.
Ihssen Julian, Kowarik Michael, Dilettoso Sandro, Tanner Cyril, Wacker Michael, Thöny-Meyer Linda   +5 more
doaj   +1 more source

Glycolipid‐peptide conjugate vaccines elicit CD8+ T‐cell responses and prevent breast cancer metastasis

Clinical & Translational Immunology, 2022
Objectives Metastasis is the principal cause of breast cancer mortality. Vaccines targeting breast cancer antigens have yet to demonstrate clinical efficacy, and there remains an unmet need for safe and effective treatment to reduce the risk of ...
Olivia K Burn, Kathryn Farrand, Tara Pritchard, Sarah Draper, Ching‐wen Tang, Anna H Mooney, Alfonso J Schmidt, Sung H Yang, Geoffrey M Williams, Margaret A Brimble, Matheswaran Kandasamy, Andrew J Marshall, Kate Clarke, Gavin F Painter, Ian F Hermans, Robert Weinkove   +15 more
doaj   +1 more source

Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site‐Specific Integration of CFTR and Mutation‐Agnostic Disease Rescue

Advanced Functional Materials, EarlyView.
Lipid nanoparticles (LNPs) are optimized to co‐deliver Cas9‐encoding messenger RNA (mRNA), a single guide RNA (sgRNA) targeting the endogenous cystic fibrosis transmembrane conductance regulator (CFTR) gene, and homologous linear double‐stranded donor DNA (ldsDNA) templates encoding CFTR.
Ruth A. Foley, Paul G. Ayoub, Vrishti Sinha, Colin Juett, Alicia Sanoyca, Emily C. Duggan, Lindsay E. Lathrop, Priyanka Bhatt, Kevin Coote, Beate Illek, Brigitte N. Gomperts, Donald B. Kohn, Steven J. Jonas   +12 more
wiley   +1 more source

Development of a novel glycoengineering platform for the rapid production of conjugate vaccines

Microbial Cell Factories, 2023
Conjugate vaccines produced either by chemical or biologically conjugation have been demonstrated to be safe and efficacious in protection against several deadly bacterial diseases.
Sherif Abouelhadid, Elizabeth R. Atkins, Emily J. Kay, Ian J. Passmore, Simon J. North, Burhan Lehri, Paul Hitchen, Eirik Bakke, Mohammed Rahman, Janine T. Bossé, Yanwen Li, Vanessa S. Terra, Paul R. Langford, Anne Dell, Brendan W. Wren, Jon Cuccui   +15 more
doaj   +1 more source

Synergistic Osteogenesis After Co‐Administration of cmRNAs Encoding BMP‐2 and BMP‐7 Utilizing a Transcript‐Activated Matrix

Advanced Functional Materials, EarlyView.
This study demonstrates that the dual delivery of BMP‐2/‐7 coding cmRNAs for bone healing is demonstrated as feasible, safe, and highly osteogenic. Compared to single BMP‐2 or BMP‐7 cmRNAs, the combination enhances the production of both mineral and organic components of the extracellular matrix when delivered using a collagen‐HA scaffold, supporting ...
Claudia Del Toro Runzer, Joanna M. Sadowska, Nadia Roumans, Christian Plank, Christopher H. Evans, Fergal J. O'Brien, Martijn van Griensven, Elizabeth R. Balmayor   +7 more
wiley   +1 more source

Bacterial Vaccines and Serotype Replacement: Lessons from Haemophilus influenzae and Prospects for Streptococcus pneumoniae

Emerging Infectious Diseases, 1999
Conjugate vaccines have reduced the incidence of invasive disease caused by Haemophilus influenzae, type b (Hib), in industrialized countries and may be highly effective against Streptococcus pneumoniae.
Marc Lipsitch
doaj   +1 more source

Herd Protection against Meningococcal Disease through Vaccination

Microorganisms, 2020
Reduction in the transmission of Neisseria meningitidis within a population results in fewer invasive disease cases. Vaccination with meningococcal vaccines composed of high weight capsular polysaccharide without carrier proteins has minimal effect ...
Stephen A. Clark, Ray Borrow
doaj   +1 more source

Next‐Generation Bio‐Reducible Lipids Enable Enhanced Vaccine Efficacy in Malaria and Primate Models

Advanced Functional Materials, EarlyView.
Structure–activity relationship (SAR) optimization of bio‐reducible ionizable lipids enables the development of highly effective lipid nanoparticle (LNP) mRNA vaccines. Lead LNPs show superior tolerability and antibody responses in rodents and primates, outperforming approved COVID‐19 vaccine lipids.
Ruben De Coen, Sabah Kasmi, Shrinivas Dumbre, Lies Baekens, Elise Seynaeve, Louise Van den Hauwe, Niccolò Cantini, Aello Garantoudi, Filipe Branco Madeira, Alain Marrot, Emma Tuypens, Sofie Seghers, Anna Kuchmiy, Elisabeth Brabants, Bart Vanderborght, Ine Maes, Sarah Vandenberghe, Jessica Filtjens, Alícia Gordún Peiró, Daliya Kancheva, Ayla Debraekeleer, Florence Lambolez, Emily De Lombaerde, Yong Chen, Rafael Miyazawa Martins, Pauline Formaglio, Damya Laoui, Sofie Deschoemaeker, Bruno G. De Geest, Rogerio Amino, Stefaan De Koker   +30 more
wiley   +1 more source

Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines

Molecules, 2018
Many malignant cell surface carbohydrates resulting from abnormal glycosylation patterns of certain diseases can serve as antigens for the development of vaccines against these diseases.
Qingjiang Li, Zhongwu Guo
doaj   +1 more source

Inactivating SARS‐CoV‐2 Virus with MOF‐Composites as Smart Face Masks

Advanced Functional Materials, EarlyView.
In situ preparation and functionalization of MOF@Cotton fabrics as smart face masks for the immobilization of proteins and inactivation viruses, such as SARS‐CoV‐2. Abstract The significant impact of the SARS‐CoV‐2 (COVID‐19) pandemic outbreak on people's lives has highlighted the urgent need for effective personal protective equipment.
Romy Ettlinger, Aamod V. Desai, Hau Lam Jody Cheong, Louise L. Major, Terry K. Smith, Aaron B. Naden, Jane Hilton, Catherine S. Adamson, A. Robert Armstrong, Russell E. Morris   +9 more
wiley   +1 more source